Disease-Specific Derangement of Circulating Endocannabinoids and N-Acylethanolamines in Myeloproliferative Neoplasms

Dorian Forte, Flaminia Fanelli, Marco Mezzullo, Martina Barone, Giulia Corradi, Giuseppe Auteri, Daniela Bartoletti, Marina Martello, Emanuela Ottaviani, Carolina Terragna, Antonio Curti, Uberto Pagotto, Francesca Palandri, Michele Cavo, Lucia Catani. Int J Mol Sci. 2020;21(9):3399.

Observational studyHumans

Design

Observational study

Subjects

55 patients with myeloproliferative neoplasms (41 myelofibrosis, 9 polycythaemia vera, 5 essential thrombocythaemia) and 10 healthy controls

Dose used in the study

No palmitoylethanolamide was given; plasma levels were measured

Duration

Not stated in the abstract

What was measured

Plasma anandamide, palmitoylethanolamide, oleoylethanolamide, 2-AG and 1-AG by LC-MS/MS, compared across disease subtypes and with platelet count, JAK2V617F allele burden, splenomegaly and risk class.

What the authors reported

The study found:

• Overall, patients had lipid levels similar to controls.
• Anandamide correlated with platelet count.
• Myelofibrosis patients had higher 2-AG plus 1-AG than the other subtypes, higher OEA/AEA ratios than controls and ET patients, and higher OEA/PEA ratios than controls.
• The 2-AG plus 1-AG sum correlated with JAK2V617F allele frequency and splenomegaly.

Limits of this study

A small observational study with only 10 controls and 5 to 41 patients per subtype; it describes blood levels, not effects of taking PEA. The authors declare no conflicts of interest.

Source

PubMed 32403407 · doi:10.3390/ijms21093399

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.